Evidence map›Paper›PMID 39048371›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Lorlatinib for the Treatment of Inflammatory Myofibroblastic Tumor after Allogeneic Hematopoietic Stem Cell Transplantation.

Toshinari Yagi, Yoji Kukita, Haruki Matsuoka, Toru Wakamatsu, Hironari Tamiya, Makiyo Watanabe, Shigeki Kakunaga, Satoshi Takenaka, Chiaki Kubo, Yoshiko Hashii and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Toshinari YagiDepartment of Outpatient Chemotherapy, Osaka International Cancer Institute, Japan.
Yoji KukitaLaboratory of Genomic Pathology, Osaka International Cancer Institute, Japan.
Haruki MatsuokaDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Japan.
Toru WakamatsuDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Japan.
Hironari TamiyaDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Japan.
Makiyo WatanabeDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Japan.
Shigeki KakunagaDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Japan.
Satoshi TakenakaDepartment of Orthopedic Surgery, Osaka International Cancer Institute, Japan.
Chiaki KuboDepartment of Pathology, Osaka International Cancer Institute, Japan.
Yoshiko HashiiDepartment of Pediatrics, Osaka International Cancer Institute, Japan.
Katsuyuki NakanishiDepartment of Diagnostic and Interventional Radiology, Osaka International Cancer Institute, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory myofibroblastic tumors (IMTs) are rare sarcomas composed of myofibroblastic and fibroblastic cells, accompanied by inflammatory cell infiltration. Many IMTs exhibit clonal rearrangement of anaplastic lymphoma kinase (ALK). We herein report a 56-year-old woman with uterine IMT harboring a thrombospondin-1::ALK fusion that developed after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Laboratory data before systemic therapy indicated increased interleukin-6 and severe leukocytosis. The patient was treated with lorlatinib; however, the response duration was approximately two months. Similar case reports need to be compiled and evaluated to elucidate the efficacy of lorlatinib in post-allo-HSCT IMT with ALK rearrangement.

Indexed as

Hematopoietic Stem Cell TransplantationLactams, MacrocyclicNeoplasms, Muscle TissueAminopyridinesAnaplastic Lymphoma KinaseFemaleHumansLactamsMiddle AgedPyrazolesTransplantation, HomologousTreatment OutcomeALK protein, humanAminopyridinesAnaplastic Lymphoma KinaseLactamsLactams, MacrocycliclorlatinibPyrazolesallogeneic hematopoietic stem cell transplantationinflammatory myofibroblastic tumorinterleukin-6lorlatinibTHBS1::ALK

Identifiers

PMID39048371
PMCPMC11949658

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.